



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Evobrutinib

Cat. No.:	HY-101215
CAS No.:	1415823-73-2
Molecular Formula:	C ₂₅ H ₂₇ N ₅ O ₂
Molecular Weight:	429.51
Target:	Btk
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 33.33 mg/mL (77.60 mM; Need ultrasonic)				
	Preparing Stock Solutions	Solvent Concentration Mass	1 mg	5 mg	10 mg
			1 mM	2.3282 mL	11.6412 mL
		5 mM	0.4656 mL	2.3282 mL	4.6565 mL
		10 mM	0.2328 mL	1.1641 mL	2.3282 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.84 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (4.84 mM); Clear solution				
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.84 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	Evobrutinib (M2951) is an orally active, potent, highly selective and irreversibly covalent BTK inhibitor, with an IC ₅₀ of 8.9 nM. Evobrutinib (M2951) can be used for the research of autoimmune diseases ^[1] .
IC ₅₀ & Target	IC ₅₀ : 8.9 nM (BTK) ^[1]
In Vivo	Evobrutinib (0.3, 1, 3, 10, or 30 mg/kg, oral gavage, once daily) demonstrates efficacy in a rat model of rheumatoid arthritis ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female Lewis rats with semi-established type II collagen arthritis ^[1] .
Dosage:	0.3, 1, 3, 10, or 30 mg/kg.
Administration:	Oral gavage once daily for 11 days (days 6-16).
Result:	Reduced ankle histopathology scores in a dose-dependent manner, compared to vehicle.

CUSTOMER VALIDATION

- Mol Syst Biol. 2023 Dec 18.
- Thromb Haemost. 2019 Mar;119(3):397-406.
- Eur J Pharmacol. 2021 Dec 8;914:174690.
- Drug Test Anal. 2019 Jan;11(1):129-139.
- Biomed Chromatogr. 2019 May;33(5):e4507.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Caldwell R, et al. Discovery of Evobrutinib: An Oral, Potent and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases. J Med Chem. 2019 Aug 1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA